Larimar Therapeutics, Inc. (LRMR)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.32-15.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · LRMR
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Worth watching into the next print: this name operates in a high-miss-rate industry and is a smaller-cap name (higher miss base rate). A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers · Company calendar date is not available
LRMR — earnings miss
Dated 2026-03-19
Results of Operations and Financial Condition. On March 19, 2026, Larimar Therapeutics, Inc. (the “ Company ”) announced its financial results and operational highlights for the fourth quarter of 2025 and for the year ended December 31, 2025. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information furnished pursuant to this Item 2.02, including Exhibit 99.1 attached hereto, is intended to be fur…
Why it matters: Skin FXN is central to Larimar's proposed approval path. Long-term results can show whether the rise lasts with daily dosing.
Supportive ifIn a new update, at least 80% of participants with six-month data remain above 8.2 pg/µg skin FXN.
Worry ifIn a new update, fewer than half of participants with six-month data remain above 8.2 pg/µg. Or levels fall over time.
Why it matters: The FDA said the study should be underway when Larimar submits its BLA. First dosing also marks progress on the confirmatory trial.
Supportive ifLarimar reports that the first patient received a dose in the global Phase 3 study by September 30, 2026.
Worry ifLarimar has not dosed the first patient by September 30, 2026, or reports a delay to the trial start.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$316 on $10,000 · ±3.2% | How much price usually moves either way. |
| Bad day | $750 loss on $10,000 · 7.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,655 loss on $10,000 · 66.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.